EUVIMEDEUVIMED entdecken
Crossref

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan

Jalpa A Doshi iD, Pengxiang Li, Shravan Asthana iD, John K Lin iD

JCO Oncology Practice · 25.04.2025

DOI: 10.1200/op-24-00937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 25.04.2025. Verfasst von Jalpa A Doshi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Medicare Part D beneficiaries who do not qualify for low-income subsidies face high out-of-pocket (OOP) costs for brand-name specialty oral anticancer medications (SOAMs). We calculated how OOP costs for such SOAMs might evolve on the basis of the Inflation Reduction Act’s (IRA) Part D benefit changes. METHODS We calculated OOP costs for 10 commonly used brand-name SOAMs across various cancers under four Part D benefit scenarios: (1) 2023: before IRA implementation (pre-IRA), (2) 2024: an annual OOP maximum set at the catastrophic threshold during initial IRA implementation (mid-IRA), (3) 2025: an annual OOP maximum set at $2,000 in US dollars (USD) after final IRA implementation (post-IRA, default), and (4) 2025: $2,000 USD annual OOP maximum and voluntary enrollment in the Medicare Prescription Payment Plan (MPPP) to smooth OOP costs via monthly payments (post-IRA, opt-in MPPP). RESULTS In 2023 (pre-IRA), annual OOP costs for SOAMs ranged from $11,143 USD to $20,592 USD. In 2024 (mid-IRA) and 2025 (post-IRA), beneficiaries would only pay the new OOP maximums of $3,333 USD and $2,000 USD, respectively, regardless of SOAM prescribed or treatment duration. In 2025, the $2,000 USD OOP amount would be entirely frontloaded in January unless beneficiaries enroll in the MPPP, which could lower their OOP costs to just $167 USD for January and each calendar month thereafter, regardless of SOAM prescribed or treatment duration. CONCLUSION Although the annual OOP maximum enacted by the IRA will decrease OOP costs significantly for Medicare beneficiaries treated with brand-name SOAMs beginning 2025, enrollment in the MPPP is critical to avoid patients owing the entire $2,000 USD in January alone. Oncology providers have a critical role to play in ensuring beneficiaries are aware of the option to smooth their OOP costs via MPPP enrollment.

Autor:innen und Institutionen

  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA.
  • Feinberg School of Medicine, Northwestern University, Chicago, IL.
  • University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Jalpa A Doshi, Shravan Asthana, John K Lin

Zitieren

APA

Doshi, J. A., Li, P., Asthana, S., & Lin, J. K. (2025). Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan. JCO Oncology Practice. https://doi.org/10.1200/op-24-00937

Vancouver

Doshi JA, Li P, Asthana S, Lin JK. Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan. JCO Oncology Practice. 2025. doi:10.1200/op-24-00937

BibTeX
@article{Doshi2025,
  author = {Doshi, Jalpa A and Li, Pengxiang and Asthana, Shravan and Lin, John K},
  title = {Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op-24-00937}
}
Kostenlos starten →